PB1926: REAL-WORLD ERYTHROPOIESIS-STIMULATING AGENT (ESA) TREATMENT PATTERNS AND OUTCOMES AMONG US PATIENTS WITH LOWER-RISK MYELODYSPLASTIC SYNDROMES (LR-MDS)
Main Authors: | S. Mukherjee, K. Zimmerman Savill, A. Gajra, J. Kish, C. Brown-Bickerstaff, D. Gentile, A. Falkenstein, T. Miller, J. Laney, A. McBride |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2022-06-01
|
Series: | HemaSphere |
Online Access: | http://journals.lww.com/10.1097/01.HS9.0000850556.55678.1f |
Similar Items
-
P781: CLINICAL OUTCOMES AND HEALTHCARE RESOURCE UTILIZATION (HCRU) IN PATIENTS WITH LR-MDS REINITIATING ESAS FOLLOWING PREVIOUS ESA TREATMENT
by: G. Garcia-Manero, et al.
Published: (2022-06-01) -
EFFICACY AND SAFETY OF LUSPATERCEPT VERSUS EPOETIN ALFA IN ERYTHROPOIESIS-STIMULATING AGENT (ESA)-NAIVE PATIENTS WITH TRANSFUSION-DEPENDENT LOWER-RISK MYELODYSPLASTIC SYNDROMES (LR-MDS): FULL ANALYSIS OF THE COMMANDS TRIAL
by: G. Garcia-Manero, et al.
Published: (2024-01-01) -
PB2263: SUPPORTIVE CARE IN LOW-RISK MYELODYSPLASTIC SYNDROMES: ROLE OF ERYTHROPOIESIS STIMULATING AGENTS (ESAS)
by: C. Cerchione, et al.
Published: (2022-06-01) -
Treatment patterns and outcomes with luspatercept in patients with lower‐risk myelodysplastic syndromes: A retrospective US cohort analysis
by: Sudipto Mukherjee, et al.
Published: (2024-01-01) -
P733: TREATMENT PATTERNS AND OUTCOMES AMONG PATIENTS WITH LOWER-RISK MYELODYSPLASTIC SYNDROMES RECEIVING LUSPATERCEPT IN ROUTINE CLINICAL PRACTICE IN THE UNITED STATES
by: Sudipto Mukherjee, et al.
Published: (2023-08-01)